Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03410901 · ClinicalTrials.gov registry record · Phase 1
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
A Phase 1 study, sponsored by Ronald Levy.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03410901 is a Phase 1 study that has completed, run by Ronald Levy. The registered enrollment target is 14 participants.
The verdict
NCT03410901, a Phase 1 study, has completed, sponsored by Ronald Levy.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of the anti-OX40 antibody BMS-986178 when given together with the TLR9 agonist SD-101 and radiation therapy in treating patients with low-grade B-cell Non-Hodgkin lymphomas. TLR9 agonist SD-101 may stimulate the immune system in different ways and stop cancer cells from growing. Anti-OX40 antibody is a monoclonal antibody that enhances the activation of T cells, immune cells that are important for fighting tumors Radiation therapy uses high energy x-rays to kill cancer cells and may make them more easily detected by the immune system. Giving TLR9 agonist SD-101 together with anti-OX40 antibody BMS 986178 and radiation therapy may work better in treating patients with low-grade B-cell non-hodgkin lymphomas.
Interventions
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
- BIOLOGICAL Anti-OX40 Antibody BMS 986178
- DRUG TLR9 Agonist SD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2024-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03410901
The ClinicalTrials.gov registry entry for NCT03410901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ronald Levy, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03410901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03410901 about?
NCT03410901 is a clinical study titled "TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas". This phase I trial studies the side effects and best dose of the anti-OX40 antibody BMS-986178 when given together with the TLR9 agonist SD-101 and radiation therapy in treating patients with low-grade B-cell Non-Hodgkin lymphomas. TLR9 agonist SD-101 may stimulate the immune system in different way...
What is the current status of trial NCT03410901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2018-04-09. Estimated completion is 2024-10-10.
What interventions are being tested in trial NCT03410901?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION), Anti-OX40 Antibody BMS 986178 (BIOLOGICAL), TLR9 Agonist SD-101 (DRUG).
Who is sponsoring clinical trial NCT03410901?
This trial is sponsored by Ronald Levy, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.